Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PreveCeutical (PREV) files a PCT (Patent Cooperation Treaty) application for D-amino acid peptides
  • The patent aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer
  • This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project
  • These peptides have the potential, at least in part, to work as an MMP inhibitor
  • CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news
  • PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products
  • PreveCeutical Medical (PREV) opened trading at C$0.025

PreveCeutical Medical (PREV) filed a PCT (Patent Cooperation Treaty) application number on November 18.

The company aims to be a leader in the preventive health sciences sector.

For this application, the company entitled the patent, “Peptides and Uses Thereof,” which aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer.

D-Amino is an amino acid comprising d-serine and d-aspartate. Found in the human body, they are the two most commonly studied acids in the human body.

This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project.

These peptides have the potential, at least in part, to work as an MMP inhibitor.

Stephen Van Deventer has assigned any and all of its rights in the invention and patent to the company.

CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news.

“This patent will protect the peptides which have the potential for cancer treatments. We are actively seeking partners to work with for these treatments. As my further dedication and commitment to PreveCeutical, I have assigned my inventor and patent rights to the company free of charge.”

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products.

PreveCeutical Medical (PREV) opened trading at C$0.025


More From The Market Herald
The Market Herald Video

" Trillion Energy (CSE:TCF) to commence 3D seismic reprocessing project for SASB

Trillion Energy (TCF) has announced the commencement of its 3D seismic reprocessing project for SASB.
The Market Herald Video

" CanadaBis Capital (TSXV:CANB) provides shareholder update

CanadaBis Capital (CANB) provided an update for shareholders and highlighted its financial performance over the past four quarters.
The Market Herald Video

" Silver Bullet Mines (TSXV:SBMI) discovers new sulphide vein structures at its Buckeye Silver Mine

Silver Bullet Mines Corp. (SBMI) reported results from its Buckeye Silver Mine in Arizona.
The Market Herald Video

" Osino Resources (TSXV:OSI) progresses with definitive feasibility study for Twin Hills Gold

Osino Resources (OSI) has provided an update on its definitive feasibility study at Twin Hills Gold.